NCT03287778View on ClinicalTrials.gov

Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions
Tardive DyskinesiaAntipsychotic Agents
Interventions
DIETARY_SUPPLEMENT

Pyridoxine

Max dose of 400 mg QD PO

DIETARY_SUPPLEMENT

Placebo

Matching placebos will be administered.

Trial Locations (1)

27599

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

Foundation of Hope, North Carolina

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT03287778 - Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia | Biotech Hunter | Biotech Hunter